Kintegral Advisory’s Edwards Lifesciences EW Stock Holding History

Kintegral Advisory’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.51M	Buy	63,868 +361	+0.6%	+$32.1K	0.43%	53
2026 Q2	$5.74M	Hold	63,507	–	–	0.47%	49
2026 Q1	$5.09M	Sell	63,507 -2,816	-4%	-$232K	0.48%	51
2025 Q4	$5.65M	Sell	66,323 -1,815	-3%	-$149K	0.48%	52
2025 Q3	$5.3M	Sell	68,138 -305	-0.4%	-$23.8K	0.45%	62
2025 Q2	$5.35M	Sell	68,443 -103	-0.2%	-$7.68K	0.49%	58
2025 Q1	$4.97M	Sell	68,546 -230	-0.3%	-$16.5K	0.5%	58
2024 Q4	$5.09M	Sell	68,776 -3,204	-4%	-$224K	0.48%	55
2024 Q3	$4.75M	Sell	71,980 -943	-1%	-$68.5K	0.44%	69
2024 Q2	$6.74M	Buy	72,923 +40,223	+123%	+$3.56M	0.65%	35
2024 Q1	$3.12M	Sell	32,700 -102	-0.3%	-$8.57K	0.31%	90
2023 Q4	$2.5M	Sell	32,802 -208	-0.6%	-$14.5K	0.28%	99
2023 Q3	$2.29M	Sell	33,010 -20	-0.1%	-$1.61K	0.28%	97
2023 Q2	$3.12M	Hold	33,030	–	–	0.37%	83
2023 Q1	$2.73M	Sell	33,030 -1,775	-5%	-$140K	0.35%	91
2022 Q4	$2.6M	Buy	34,805 +8,697	+33%	+$670K	0.34%	95
2022 Q3	$2.16M	Hold	26,108	–	–	0.3%	88
2022 Q2	$2.48M	Buy	26,108 +553	+2%	+$57.2K	0.32%	82
2022 Q1	$3.01M	Buy	25,555 +571	+2%	+$64.1K	0.33%	79
2021 Q4	$3.24M	Hold	24,984	–	–	0.34%	71
2021 Q3	$2.83M	Hold	24,984	–	–	0.33%	73
2021 Q2	$2.59M	Hold	24,984	–	–	0.31%	82
2021 Q1	$2.09M	Hold	24,984	–	–	0.27%	95
2020 Q4	$2.28M	Hold	24,984	–	–	0.31%	82
2020 Q3	$1.99M	Sell	24,984 -804	-3%	-$62.7K	0.3%	82
2020 Q2	$1.78M	Hold	25,788	–	–	0.29%	85
2020 Q1	$1.62M	Buy	25,788 +2,886	+13%	+$208K	0.32%	84
2019 Q4	$1.78M	Hold	22,902	–	–	0.32%	88
2019 Q3	$1.68M	Hold	22,902	–	–	0.33%	87
2019 Q2	$1.41M	Hold	22,902	–	–	0.29%	99
2019 Q1	$1.46M	Buy	22,902 +7,251	+46%	+$414K	0.31%	93
2018 Q4	$799K	Buy	+15,651	New	+$792K	0.24%	99

Other funds holding EW

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Ninety One Cape Town, South Africa $2B AUM 34.6% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Kintegral Advisory's EW Position: Q3 2026 in Review

Kintegral Advisory increased its Edwards Lifesciences (EW) stake by 0.57% in Q3 2026, buying an estimated $32.1K and bringing the position to 63,868 shares worth $5.51M. The position accounts for 0.43% of the portfolio, ranked #53.

Kintegral Advisory first reported a position in EW in Q4 2018 and has held it in 32 quarters since. The position peaked at $6.74M in Q2 2024. 228 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Kintegral Advisory held 63,868 shares of Edwards Lifesciences worth $5.51M as of Q3 2026.
Kintegral Advisory bought 361 Edwards Lifesciences shares in Q3 2026, an estimated $32.1K.
Edwards Lifesciences made up 0.43% of Kintegral Advisory's portfolio in Q3 2026, its #53 holding.
Kintegral Advisory first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 32 quarters since.
Kintegral Advisory's Edwards Lifesciences position peaked at $6.74M in Q2 2024.
228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Kintegral Advisory's 13F filing for Q3 2026, filed 16 Oct 2026.